Saturday 17 October 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.17
0.01
−5.56%
Follow ATYR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(103.49%) | (108.11%) | (105.62%) | (98.67%) | |
| (75.78%) | (78.09%) | (79.17%) | (70.97%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(91.88%) | (106.87%) | (116.49%) | (119.01%) | |
Average Days of Receivables |
34.07 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.65) | (0.67) | (0.60) | (0.56) | |
Free Cash Flow |
(63.00) | (62.07) | (59.29) | (54.81) | |
Capital Expenditures |
(0.08) | (0.08) | (0.20) | (0.27) | |
| Other line items | |||||
Cash ROIC |
(36.92%) | (42.44%) | (47.66%) | (51.68%) | |
Accounts Receivable Turnover |
7.77 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
551.38% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
154.83% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
40.85% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.84 | 0.84 | 0.90 | |
Depreciation/Fixed assets |
(0.20) | (0.07) | (0.01) | 0.07 | |
Capex/Depreciation |
0.09 | 0.28 | 9.23 | (0.87) | |
Revenue per Share |
0.11 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.65) | (0.67) | (0.60) | (0.56) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 |
Columns are period end dates